Presentation is loading. Please wait.

Presentation is loading. Please wait.

Connective Tissue Oncology Society 11th Annual Meeting NON METASTATIC EWING’ FAMILY TUMORS: HIGH DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM CELL RESCUE.

Published byMorgan Roberts Modified over 8 years ago

Similar presentations

Presentation on theme: "Connective Tissue Oncology Society 11th Annual Meeting NON METASTATIC EWING’ FAMILY TUMORS: HIGH DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM CELL RESCUE."— Presentation transcript:

1 Connective Tissue Oncology Society 11th Annual Meeting NON METASTATIC EWING’ FAMILY TUMORS: HIGH DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM CELL RESCUE IN POOR RESPONDER PATIENTS: PRELIMINARY RESULTS OF ISG/SSG III PROTOCOL. S.Ferrari, A.Tienghi, M.Mercuri, F.Bertoni, E.Barbieri, F.Fossati Bellani, R. Luksch, G. Bernini, A. Brach del Prever, F.Fagioli, P.Picci and G. Bacci Italian Sarcoma Group (ISG); S. Smeland, T. Bohling, O. Brosjo, G Saeter, T. Wiebe, T Alvegaard Scandinavian Sarcoma Group (SSG)

2 Diagnosis of Ewing/PNET Sarcoma No metastases at diagnosis Age between 3-40 years Non-randomized clinical study Induction treatment V-Ac-C-A-I-E Local treatment Surgery whenever possible, Radiotherapy, when surgery is not feasible, or in case of inadequate surgical margins or in case of inadequate surgical margins Maintenance treatment According to the response to induction therapy

3 ISG/SSG III Evaluation of response Good Response Surgery: Surgery: histologic response G II-III (Picci) RxT: RxT: CR to soft tissue Poor response Surgery: Surgery: histologic response G I (Picci) RxT: RxT: persistent disease in soft tissue

4 VACVIDVACIE VACVIDIEVACVIDVACVID IEVACCEBuMel Local treatment GR PR PBSC harvest ISG SSG III VAC V=vincristine 1.5mg/m2 A=doxorubicin 80mg/m2 C=cyclophosphamide 1200 mg/m2 I = ifosfamide 3g/m2/day x 3 D=dactinomycin 1.5mg/m2 E=etoposide 150mg/m2/day x3 C=cyclophosphamide 4000mg/m2 E=etoposide 200mg/m2x3 Bu=busulfan 16mg/kg Mel=melphalan 140mg/m2

5 ISG/SSG III Clinical Characteristics GENDERMaleFemale 152 (63%) 88 (37%) FEVER Available in 225 YesNo 29 (13%) 196 (87%) FATIGUE Available in 216 YesNo 17 (8%) 199 (92%) Weightloss Available in 214 YesNo 11 (5%) 203 (95%) SAP Available in 209 NormalHigh 185 (89%) 24 (11%) 24 (11%) LDH Available in 207 NormalHigh 145 (70%) 62 (30%) SiteExtremityCentralPelvis 130 (54%) 65 (27%) 45 (19%) 45 (19%) Median age (years): 15 (3-40) Median duration of symptoms (months): 4 (0.5-38 ) June 1999 - September 2005 240 patients 240 patients ISG: 203 (85%) SSG: 37 (15%)

6 ISG/SSG III Local treatment Surgery 134 (59%) Surgery + RxT 49 (21%) RxT 45 (20%) 228 patients

7 ISG/SSG III Local treatment by site P < 0.0001

8 ISG/SSG III SURGERY Surgery Resection 175 (95%) Amputation 9 (5%) 184 patients Margins Wide 128 (80%) Radical 6 (4%) Marginal 18 (11%) Intralesional 8 (5%) 160 patients

9 ISG/SSG III Response Response Good 111 (50%) Poor 110 (50%) 221 patients Necrosis I 77 (49%) II 38 (24%) III 43 (27%) 158 patients

10 ISG/SSG III Response by site P=0.043

11 ISG/SSG III Histologic response by site P=0.4

12 ISG/SSG III ISG/SSG % (95% CI) % (95% CI) 3-year PFS 67 (60-75) 3-year OS 78 (72-85) Median FU 29 months (1-75) Progression-free survivalOverall survival

13 ISG/SSG III Progression-free survival SITE Extremity 3 yrs PFS 70% (61-80) Central 3 yrs PFS 62% (46-77) Pelvis 3 yrs PFS 60% (43-76) P=0.3

14 ISG/SSG III Progression-free survival Local treatment Surgery 3 yrs PFS 72% (63-81) Surgery+RxT 3 yrs PFS 68% (52-83) RxT 3 yrs PFS 51% (33-68) RxT No PD 3 yrs PFS 57% (39-76) P =0.09

15 ISG/SSG III Progression-free survival RESPONSE GR 3 yrs PFS 70% (61-80) PR 3 yrs PFS 62% (51-73) P=0.19

16 ISG/SSG III No High Dose Chemotherapy 22/110 poor responder patients did not get HDC PD6 Poor harvest2 Medical contraindication4 Refusal/medical decision10

17 ISG/SSG III Progression-free survival RESPONSE GR 3 yrs PFS 70% (61-80) PR 3 yrs PFS 68% (57-80) P=0.7

18 ISG/SSG III Progression-free survival HISTOLOGIC RESPONSE I 3 yrs PFS 66% (54-79) II 3 yrs PFS 70% (55-86) III 3 yrs PFS 83% (70-95) P=0.18

19 ISG/SSG III Events PDLRLR+otherBoneLungBone+Lung 6 (11%) 10 (18%) 8 (14%) 18 (32%) 6 (11%) G4 cardiotox, Pneumonia, Septic emboli 10 months after chemo completion AML 2 patients

20 The treatment is feasible and well tolerated Results are encouraging The strategy for poor responders seems to improve their prognosis Longer follow-up is needed to confirm its efficacy ISG SSG III

Download ppt "Connective Tissue Oncology Society 11th Annual Meeting NON METASTATIC EWING’ FAMILY TUMORS: HIGH DOSE CHEMOTHERAPY WITH PERIPHERAL BLOOD STEM CELL RESCUE."

Similar presentations

Pulmonary Stereotactic Ablative Radiotherapy:

Pulmonary Stereotactic Ablative Radiotherapy:
An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma.
Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,

Treatment of Relapsed Osteosarcoma After Contemporary Therapy: The Memorial Sloan-Kettering Experience Chou AJ, Merola PR, Vyas Y, Wexler L, Gorlick R,
I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days 1 2 22 36 50 64 92 E V A L U A.

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.
Our bold approach to life-changing medicines

Our bold approach to life-changing medicines
Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.
Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.

Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)

IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
15th Annual CTOS Meeting November 5–7, 2009 PRELIMINARY RESULTS OF A RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH METHOTREXATE (MTX), CISPLATIN (CDP),

15th Annual CTOS Meeting November 5–7, 2009 PRELIMINARY RESULTS OF A RANDOMIZED TRIAL OF NEOADJUVANT CHEMOTHERAPY WITH METHOTREXATE (MTX), CISPLATIN (CDP),
62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.
GOS Paediatric Sarcoma Surgery Combined UCL Sarcoma Service GOS Oncology and London Bone and Soft Tissue Tumour Service UCLH.

GOS Paediatric Sarcoma Surgery Combined UCL Sarcoma Service GOS Oncology and London Bone and Soft Tissue Tumour Service UCLH.
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.

Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;

CO-I KNTM/K i CzS M. Sklodowska-Curie Memorial Cancer Center-Institute of Oncology Medical University of Warsaw; Warsaw, POLAND Medical University of Gdansk;
Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup 62005 study.

Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross- match comparison in the EORTC Intergroup study.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
BONE CANCER RAED ISSOU.

BONE CANCER RAED ISSOU.
Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

Similar presentations

Ads by Google